Chief, Lymphoid Malignancies Branch;
NIH Distinguished Investigator
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, Maryland
For pioneering contributions to the molecular classification of diffuse large B-cell lymphoma (DLBCL) including the identification of clinically distinct DLBCL subtypes through genomic profiling and the development of functional genomic screens to uncover new therapeutic targets. His discovery that activated B cell-like DLBCL relies on chronic B-cell receptor (BCR) signaling led to the development of targeted therapies, including the BTK inhibitor ibrutinib, which significantly improved survival for patients with molecularly defined lymphoma subtypes. Dr. Staudt’s continued leadership in refining lymphoma taxonomy and advancing novel combination therapies exemplifies the power of precision oncology in transforming patient outcomes.
The AACR established the AACR Award for Outstanding Achievement in Blood Cancer Research to recognize an individual on the basis of their meritorious achievements and contributions to any aspect of blood cancer research and who has made a significant scientific contribution to basic, translational, or clinical research related to blood cancer or associated disorders such as myelodysplastic syndrome or myeloproliferative neoplasms. To learn more please visit the press release.
View Dr. Staudt’s Fellows of the AACR Academy page.
View Past Recipients.